sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
TREM2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations of TREM2 are associated with increased risk of Alzheimer's disease (AD). TREM2 is a type-1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (sTREM2), which can be measured in the cerebrospinal fluid (CSF). In this cross-sectional multicenter study, we investigated whether CSF levels of sTREM2 are changed during the clinical course of AD, and in cognitively normal individuals with suspected non-AD pathology (SNAP). CSF sTREM2 levels were higher in mild cognitive impairment due to AD than in all other AD groups and controls. SNAP individuals also had significantly increased CSF sTREM2 compared to controls. Moreover, increased CSF sTREM2 levels were associated with higher CSF total tau and phospho-tau181P, which are markers of neuronal degeneration and tau pathology. Our data demonstrate that CSF sTREM2 levels are increased in the early symptomatic phase of AD, probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“cerebrospinal fluid levels of soluble TREM2 are a potential biomarker for microglia activity in early-stage AD and correlate with neuronal injury markers (135, 136).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [135]
In the citing paper
“Moreover, an increase in secreted extracellular fragment of TREM2 appears to be a CSF biomarker of disease progression in AD (Suárez-Calvet et al., 2016).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Suárez-Calvet et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 7×
“Likewise, AD dementia was defined following NIA-AA criteria (McKhann et al, 2011) for probable AD, with the requirment of decreased Ab1–42 and increased T-tau and/or P-tau181P.”
BackgroundMethodInfluentialAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 8×
“Therefore, the diagnostic criteria of the present study were based both on the clinical diagnosis and on the AD CSF core biomarker profile, following NIA-AA recommendations (Albert et al, 2011; McKhann et al, 2011; Sperling et al, 2011).”
BackgroundMethodInfluentialSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 4×
“…AD, mild cognitive impairment (MCI) due to AD (MCI-AD), and AD dementia and controls, defined by clinical and CSF biomarker criteria as recommended by the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria (Albert et al, 2011; McKhann et al, 2011; Sperling et al, 2011).”
MethodInfluentialNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 3×
“Increased microglial activation and neuroinflammation frequently accompanies the early development of Ab and tau pathology (Mosher & WyssCoray, 2014; Streit et al, 2014; Heneka et al, 2015; Tanzi, 2015).”
BackgroundInfluentialSelf-citationWinblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“In brief, these subjects were clinically diagnosed as MCI (following standard criteria) (Winblad et al, 2004) or with CDR = 0.5 or CDR-SOB = 0.5–4, in combination with decreased Ab1–42 and increased T-tau and/or P-tau181P.”
BackgroundInfluentialSelf-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 4×
“However, it is very unlikely that the possibility of TREM2 mutations in the current patient sample affected our results because TREM2 mutations show a low prevalence in the population and even in AD dementia patients (Guerreiro et al, 2013a; Jonsson et al, 2013).”
BackgroundInfluentialAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 3×
“However, it is very unlikely that the possibility of TREM2 mutations in the current patient sample affected our results because TREM2 mutations show a low prevalence in the population and even in AD dementia patients (Guerreiro et al, 2013a; Jonsson et al, 2013).”
BackgroundCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · cited 1×
“…has clearly demonstrated to increase the accuracy of the diagnosis of AD, to predict whether AD is the underlying pathology responsible of the cognitive symptoms and has shown to be valuable in detecting the earlier stages of the disease (Clark et al, 2003; Shaw et al, 2009; Molinuevo et al, 2014).”
BackgroundSelf-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 3×
“Published under the terms of the CC BY 4.0 license466”
BackgroundMethodInfluentialSelf-citationTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 5×
“Data obtained from AD mouse models crossed with TREM2 knockouts are controversial by demonstrating either an increase or a decrease of amyloid plaque load (Jay et al, 2015; Wang et al, 2015).”
BackgroundMethodInfluentialFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 3×
“…January 2016 | Accepted 28 January 2016 | Published online 3 March 2016 EMBO Mol Med (2016) 8: 466–476 See also: SE Schindler & DM Holtzman (May 2016) 1 BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany 2 German Center for Neurodegenerative Diseases…”
BackgroundMethodTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 11×
“However, the AD-associated R47H mutations did not show decreased shedding in cellular models (Kleinberger et al, 2014) and was even found to be increased in CSF samples of carriers (Piccio et al, 2016).”
BackgroundMethodResultInfluentialSelf-citationPaloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 4×
“Heterozygous missense mutations in TREM2 also increase the risk for other neurodegenerative diseases (Borroni et al, 2013; Rayaprolu et al, 2013; Cuyvers et al, 2014), and homozygous loss-of-function mutations in TREM2 cause Nasu– Hakola disease (NHD) (Paloneva et al, 2002) and frontotemporal dementia (FTD)-like syndr…”
BackgroundInfluentialJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 1×
“Data obtained from AD mouse models crossed with TREM2 knockouts are controversial by demonstrating either an increase or a decrease of amyloid plaque load (Jay et al, 2015; Wang et al, 2015).”
BackgroundMicroglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603 · cited 1×
“In AD, amyloid plaques and neurofibrillary tangles, the major pathological hallmarks of the disease, develop decades before the onset of clinical symptoms (Morris et al, 1996; Braak & Braak, 1997; Hulette et al, 1998; Price & Morris, 1999).”
BackgroundJack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · cited 4×
“Published under the terms of the CC BY 4.0 license466”
BackgroundMethodInfluentialThe TREM receptor family and signal integration
Klesney-Tait, J., Turnbull, I. R., & Colonna, M. (2006) · Nature Immunology · doi:10.1038/ni1411 · Cited by 589 · cited 3×
“TREM2 is a type-1 transmembrane glycoprotein with an immunoglobulin-like extracellular domain, one transmembrane domain and a short cytosolic tail (Klesney-Tait et al, 2006).”
BackgroundA role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475 · cited 3×
“…online 3 March 2016 EMBO Mol Med (2016) 8: 466–476 See also: SE Schindler & DM Holtzman (May 2016) 1 BioMedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany 2 German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany 3 Munich Cluster for…”
BackgroundInfluentialBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 1×
“It belongs to the TREM family of innate immune receptors and is expressed in cells of the monocytic lineage (Bouchon et al, 2001; Schmid et al, 2002; Paloneva et al, 2003; Kiialainen et al, 2005).”
BackgroundBrosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8657-1 · Cited by 447 · cited 1×
“A similar pattern of change, that is a peak in earlier stages of the disease, has been described for IL-18 and MCP-1 in plasma and in IP-10 in CSF (Galimberti et al, 2006a,b; Motta et al, 2007; Craig-Schapiro et al, 2011; Brosseron et al, 2014).”
BackgroundSelf-citationThe Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2243 · Cited by 413 · cited 2×
“…center; all of them have experience in CSF biomarker determination and have participated in the Alzheimer’s Association external quality control program (Mattsson et al, 2011) and/or the Alzheimer’s Biomarkers Standardization Initiative (ABSI) for CSF biomarkers (Molinuevo et al, 2014).”
Self-citationRayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Guerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374 · cited 1×
“CSF sTREM2 levels were higher in mild cognitive impairment due to AD than in all other AD groups and controls.”
BackgroundVanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358 · cited 1×
“All centers participating use a similar standardized operating procedure (SOP) for pre-analytical sample handling and follow international consensus recommendations (Blennow et al, 2010; Vanderstichele et al, 2012).”
MethodSelf-citationClark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Schmid, C. D., Sautkulis, L. N., Danielson, P. E., Cooper, J., Hasel, K. W., Hilbush, B. S., Sutcliffe, J. G., & Carson, M. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01243.x · Cited by 351 · cited 2×
“Keywords Alzheimer’s disease; biomarkers; microglia; neurodegeneration; TREM2 Subject Categories Biomarkers & Diagnostic Imaging; Neuroscience DOI 10.15252/emmm.201506123 | Received 3 December 2015 | Revised 27 January 2016 | Accepted 28 January 2016 | Published online 3 March 2016 EMBO Mol Med…”
BackgroundInfluentialCerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · cited 7×
“However, the AD-associated R47H mutations did not show decreased shedding in cellular models (Kleinberger et al, 2014) and was even found to be increased in CSF samples of carriers (Piccio et al, 2016).”
BackgroundResultInfluentialDAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features
Paloneva, J., Mandelin, J., Kiialainen, A., Böhling, T., Prudlo, J., Hakola, P., Haltia, M., Konttinen, Y. T., & Peltonen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030027 · Cited by 318 · cited 3×
“Keywords Alzheimer’s disease; biomarkers; microglia; neurodegeneration; TREM2 Subject Categories Biomarkers & Diagnostic Imaging; Neuroscience DOI 10.15252/emmm.201506123 | Received 3 December 2015 | Revised 27 January 2016 | Accepted 28 January 2016 | Published online 3 March 2016 EMBO Mol Med…”
BackgroundInfluentialStreit, W. J., Xue, Q.-S., Tischer, J., & Bechmann, I. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0142-6 · Cited by 317 · cited 3×
“Increased microglial activation and neuroinflammation frequently accompanies the early development of Ab and tau pathology (Mosher & WyssCoray, 2014; Streit et al, 2014; Heneka et al, 2015; Tanzi, 2015).”
BackgroundInfluentialHULETTE, C. M., WELSH-BOHMER, K. A., MURRAY, M. G., SAUNDERS, A. M., MASH, D. C., & MCINTYRE, L. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199812000-00009 · Cited by 311 · cited 3×
“…of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden 19 Reta Lila Weston Laboratories and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK 20 Department of Anaesthesiology and Intensive Care, Institute of Clinical…”
BackgroundInfluentialPiccio, L., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R. E., Fenoglio, C., Rinker, J., Naismith, R. T., Panina-Bordignon, P., Passini, N., et al. (2008) · Brain · doi:10.1093/brain/awn217 · Cited by 307 · cited 6×
“The genetics at the VIB, Antwerp site was in part funded by the Belgian Science Policy Office Interuniversity Attraction Poles Program, the Flanders Government Initiated Impulse Program on Networks for Dementia Research (VIND), the Flemish government Initiated Methusalem Excellence Program, and the University of Antwe…”
BackgroundInfluentialIncreased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303 · cited 3×
“While our manuscript was under consideration, we learned that two groups independently found that CSF sTREM2 was increased in AD patients (Heslegrave et al, 2016; Piccio et al, 2016).”
BackgroundResultSelf-citationWunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296 · cited 1×
“…proteolytic processing, releasing its ectodomain into the extracellular space as a soluble variant (sTREM2) via shedding by ADAM proteases (Wunderlich et al, 2013; Kleinberger et al, 2014), and can be detected in human plasma and cerebrospinal fluid (CSF) (Piccio et al, 2008; Kleinberger…”
BackgroundMatarin, M., Salih, D. A., Yasvoina, M., Cummings, D. M., Guelfi, S., Liu, W., Nahaboo Solim, M. A., Moens, T. G., Paublete, R. M., Ali, S. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.041 · Cited by 290 · cited 1×
“Increased sTREM2 due to microglial activation is consistent with the findings that TREM2 expression (Matarin et al, 2015) and GE-180 uptake (Liu et al, 2015) are increased in elderly mouse models of AD.”
ResultIntrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease
Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289 · cited 1×
“A similar pattern of change, that is a peak in earlier stages of the disease, has been described for IL-18 and MCP-1 in plasma and in IP-10 in CSF (Galimberti et al, 2006a,b; Motta et al, 2007; Craig-Schapiro et al, 2011; Brosseron et al, 2014).”
BackgroundCraig-Schapiro, R., Kuhn, M., Xiong, C., Pickering, E. H., Liu, J., Misko, T. P., Perrin, R. J., Bales, K. R., Soares, H., Fagan, A. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018850 · Cited by 237 · cited 1×
“A similar pattern of change, that is a peak in earlier stages of the disease, has been described for IL-18 and MCP-1 in plasma and in IP-10 in CSF (Galimberti et al, 2006a,b; Motta et al, 2007; Craig-Schapiro et al, 2011; Brosseron et al, 2014).”
BackgroundSerum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209 · cited 1×
“A similar pattern of change, that is a peak in earlier stages of the disease, has been described for IL-18 and MCP-1 in plasma and in IP-10 in CSF (Galimberti et al, 2006a,b; Motta et al, 2007; Craig-Schapiro et al, 2011; Brosseron et al, 2014).”
BackgroundMolinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret‐Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.003 · Cited by 199 · cited 2×
“…has clearly demonstrated to increase the accuracy of the diagnosis of AD, to predict whether AD is the underlying pathology responsible of the cognitive symptoms and has shown to be valuable in detecting the earlier stages of the disease (Clark et al, 2003; Shaw et al, 2009; Molinuevo et al, 2014).”
BackgroundSelf-citationCuyvers, E., Bettens, K., Philtjens, S., Van Langenhove, T., Gijselinck, I., van der Zee, J., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Geerts, N., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.009 · Cited by 182 · cited 2×
“Heterozygous missense mutations in TREM2 also increase the risk for other neurodegenerative diseases (Borroni et al, 2013; Rayaprolu et al, 2013; Cuyvers et al, 2014), and homozygous loss-of-function mutations in TREM2 cause Nasu– Hakola disease (NHD) (Paloneva et al, 2002) and frontotemporal…”
BackgroundSelf-citationAltered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F., & Malaguarnera, L. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.09.002 · Cited by 176 · cited 1×
“A similar pattern of change, that is a peak in earlier stages of the disease, has been described for IL-18 and MCP-1 in plasma and in IP-10 in CSF (Galimberti et al, 2006a,b; Motta et al, 2007; Craig-Schapiro et al, 2011; Brosseron et al, 2014).”
BackgroundHeterozygous TREM2 mutations in frontotemporal dementia
Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., Fenoglio, C., Piaceri, I., Archetti, S., Bonvicini, C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.017 · Cited by 173
Van der Mussele, S., Fransen, E., Struyfs, H., Luyckx, J., Mariën, P., Saerens, J., Somers, N., Goeman, J., De Deyn, P. P., & Engelborghs, S. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140405 · Cited by 132 · cited 2×
“The cutoff values to define abnormal CSF values for each of the three AD CSF core biomarkers were defined for each center and are displayed in Appendix Table S1 (Antonell et al, 2011; Alcolea et al, 2014; Van der Mussele et al, 2014).”
BackgroundSelf-citationBelluzzi, E., Gonnelli, A., Cirnaru, M.-D., Marte, A., Plotegher, N., Russo, I., Civiero, L., Cogo, S., Carrion, M. P., Franchin, C., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0066-z · Cited by 119
Kiialainen, A., Hovanes, K., Paloneva, J., Kopra, O., & Peltonen, L. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.007 · Cited by 114 · cited 4×
“Keywords Alzheimer’s disease; biomarkers; microglia; neurodegeneration; TREM2 Subject Categories Biomarkers & Diagnostic Imaging; Neuroscience DOI 10.15252/emmm.201506123 | Received 3 December 2015 | Revised 27 January 2016 | Accepted 28 January 2016 | Published online 3 March 2016 EMBO Mol Med…”
BackgroundInfluentialLiu, B., Le, K. X., Park, M.-A., Wang, S., Belanger, A. P., Dubey, S., Frost, J. L., Holton, P., Reiser, V., Jones, P. A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0996-15.2015 · Cited by 114 · cited 1×
“Increased sTREM2 due to microglial activation is consistent with the findings that TREM2 expression (Matarin et al, 2015) and GE-180 uptake (Liu et al, 2015) are increased in elderly mouse models of AD.”
ResultAlcolea, D., Carmona-Iragui, M., Suárez-Calvet, M., Sánchez-Saudinós, M. B., Sala, I., Antón-Aguirre, S., Blesa, R., Clarimón, J., Fortea, J., & Lleó, A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140240 · Cited by 112 · cited 1×
“The cutoff values to define abnormal CSF values for each of the three AD CSF core biomarkers were defined for each center and are displayed in Appendix Table S1 (Antonell et al, 2011; Alcolea et al, 2014; Van der Mussele et al, 2014).”
Self-citationAntonell, A., Fortea, J., Rami, L., Bosch, B., Balasa, M., Sánchez‐Valle, R., Iranzo, Á., Molinuevo, J. L., & Lladó, A. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0534-0 · Cited by 55 · cited 1×
“The cutoff values to define abnormal CSF values for each of the three AD CSF core biomarkers were defined for each center and are displayed in Appendix Table S1 (Antonell et al, 2011; Alcolea et al, 2014; Van der Mussele et al, 2014).”
BackgroundSelf-citationTREM2 and Risk of Alzheimer’s Disease — Friend or Foe?
Tanzi, R. E. (2015) · New England Journal of Medicine · doi:10.1056/nejmcibr1503954 · Cited by 52 · cited 1×
“Increased microglial activation and neuroinflammation frequently accompanies the early development of Ab and tau pathology (Mosher & WyssCoray, 2014; Streit et al, 2014; Heneka et al, 2015; Tanzi, 2015).”
BackgroundEnsuring an equal playing field for antigen receptor loci variable regions
Murre, C. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.2121insight1 · Cited by 4
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Metadata
- Authors
- Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., Sánchez‐Valle, R., Antonell, A., Rami, L., Molinuevo, J. L., Brosseron, F., Traschütz, A., Heneka, M. T., Struyfs, H., Engelborghs, S., Sleegers, K., Van Broeckhoven, C., Zetterberg, H., Nellgård, B., Blennow, K., Crispin, A., Ewers, M., & Haass, C.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- Munich Cluster for Systems Neurology (DE)
- LMU Klinikum (DE)
- Universitat Autònoma de Barcelona (ES)
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES)
- Hospital Clínic de Barcelona (ES)
- Pasqual Maragall Foundation (ES)
- University Hospital Bonn (DE)
- University of Antwerp (BE)
- UCL Queen Square Institute of Neurology (GB)
- University of Gothenburg (SE)
- Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (DE)
- Corresponding author
- Ewers, Michael
- Haass, Christian
- ORCID
- Suárez‐Calvet, Marc
- Kleinberger, Gernot
- Brendel, Matthias
- Rominger, Axel
- Alcolea, Daniel
- Fortea, Juan
- Lleó, Alberto
- Blesa, Rafael
- Gispert, Juan Domingo
- Sánchez‐Valle, Raquel
- Antonell, Anna
- Rami, Lorena
- Molinuevo, José L
- Brosseron, Frederic
- Traschütz, Andreas
- Heneka, Michael T
- Engelborghs, Sebastiaan
- Sleegers, Kristel
- Zetterberg, Henrik
- Nellgård, Bengt
- Blennow, Kaj
- Crispin, Alexander
- Ewers, Michael
- Haass, Christian
- Venue
- EMBO Molecular Medicine
- Published
- 2016-03-03
- Volume
- 8
- Issue
- 5
- Pages
- 466-476
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC5120370
- OpenAlex
- W2289098957
- Cited by
- 522
- References
- 54
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 66 · 2023: 52 · 2022: 59 · 2021: 63 · 2020: 67 · 2019: 42 · 2018: 43 · 2017: 27 · 2016: 11
- FWCI
- 22.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, cc-by)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- DZNE Pub (submittedVersion, cc-by)
- Funders
- European Commission (PCIG12‐GA‐2012‐334259)
- European Research Council (FP7/2007–2013, 321366)
- Deutsche Forschungsgemeinschaft (115372)
- Cure Alzheimer's Fund
- MetLife Foundation Award
- Swedish Research Council
- Torsten Söderberg Foundation
- Royal Swedish Academy of Sciences
- Knut and Alice Wallenberg Foundation
- Frimurarestiftelsen (115372)
- University Research Fund of the University of Antwerp
- Institute Born‐Bunge
- Foundation for Alzheimer Research
- Neurosearch Antwerp
- Research Foundation—Flanders
- Agency for Innovation by Science and Technology
- Interuniversity Attraction Poles (IAP) Program of the Belgian Science Policy Office
- Flemish Government Methusalem Excellence Program, Belgium
- Flanders Impulse Program on Networks for Dementia Research
- EU Joint Program for Neurodegenerative Disease Research (321366)
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking (115372)
- Belgian Science Policy Office Interuniversity Attraction Poles Program
- Flanders Government Initiated Impulse Program on Networks for Dementia Research
- Flemish government Initiated Methusalem Excellence Program
- University of Antwerp Research Fund, Belgium
- Janssen
- ADx Neurosciences
- Innogenetics/Fujirebio Europe
- Lundbeck
- Pfizer (115372)
- Novartis
- UCB
- Roche Diagnostics
- Nutricia/Danone (115372)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- soluble TREM2, sTREM2, TREM2, microglial activation, Alzheimer's disease, cerebrospinal fluid biomarkers, mild cognitive impairment, tau protein, neuronal injury, innate immunity, early Alzheimer's disease, cognitively normal individuals
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cerebrospinal Fluid, Cross-Sectional Studies, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Receptors, Immunologic, Biomarkers, Microglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.